Batten-1 is being prepared for a Phase III trial scheduled to commence in 2026. Credit: Stock-Asso / Shutterstock.com. THX Pharma (Theranexus) and Biocodex have entered a strategic licensing agreement ...

Biocodex has acquired two licenses from THX Pharma to develop and commercialize Batten-1 worldwide and TX01 in the United States and Canada. The total deal value is up to €173 million, including a €12 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.